The FDA agrees that the Company may follow 505(b)(2) regulatory pathway to non-invasively treat basal cell carcinoma (BCC) of ...
Ever wonder how consumers feel about your franchise? Franchise Times editorial staffers check out three brands in a different ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback